• Mashup Score: 0

    Colesevelam was superior to placebo in inducing remission in patients with bile acid diarrhea with no serious adverse events reported, according to results published in The Lancet Gastroenterology & Hepatology.“Bile acid diarrhea is a common yet underrecognized cause of chronic watery diarrhea. In most countries, including the U.S., the diagnostic nuclear medicine tauroselcholic

    Tweet Tweets with this article
    • #Colesevelam boosts likelihood for clinical remission in patients with bile acid #diarrhea @LancetGastroHep #GITwitter #MedTwitter https://t.co/g1KCzcIk9Q

  • Mashup Score: 0

    Colesevelam was superior to placebo in inducing remission in patients with bile acid diarrhea with no serious adverse events reported, according to results published in The Lancet Gastroenterology & Hepatology.“Bile acid diarrhea is a common yet underrecognized cause of chronic watery diarrhea. In most countries, including the U.S., the diagnostic nuclear medicine tauroselcholic

    Tweet Tweets with this article
    • #Colesevelam was superior to placebo in inducing remission in patients with bile acid #diarrhea with no serious adverse events reported, according to results published in @LancetGastroHep #GITwitter #MedTwitter https://t.co/g1KCzcIk9Q

  • Mashup Score: 0

    The CDC issued a health advisory alerting clinicians to a spike in extensively drug-resistant shigellosis in the United States, urging them to consider this infection in cases of acute diarrhea, especially among higher risk patients.“In 2022, about 5% of Shigella infections reported to the CDC were caused by [extensively drug-resistant (XDR)] strains, compared with 0% in 2015,” the

    Tweet Tweets with this article
    • #ICYMI from @CDCgov: ‘Consider #shigellosis’ for acute #diarrhea amid surge in drug resistant cases #GITwitter #MedTwitter #Healthadvisory #CDC https://t.co/QcGeHlW2ax

  • Mashup Score: 0

    The CDC issued a health advisory alerting clinicians to a spike in extensively drug-resistant shigellosis in the United States, urging them to consider this infection in cases of acute diarrhea, especially among higher risk patients.“In 2022, about 5% of Shigella infections reported to the CDC were caused by [extensively drug-resistant (XDR)] strains, compared with 0% in 2015,” the

    Tweet Tweets with this article
    • The @CDCgov issued a #healthadvisory alerting #clinicians to a spike in extensively drug-resistant #shigellosis in the #UnitedStates, urging them to consider this infection in cases of acute #diarrhea, especially among higher risk #patients. #CDC https://t.co/QcGeHlW2ax

  • Mashup Score: 0

    Specific and nonspecific acupoint acupuncture improved symptoms of diarrhea among a small subset of patients with irritable bowel syndrome, according to results from a pilot study reported in JAMA Network Open. “Available treatments target IBS symptoms rather than underlying pathophysiological mechanisms, and additional improvements in the testing methods are still necessary. All these

    Tweet Tweets with this article
    • “The findings of this pilot randomized #clinicaltrial suggest that #acupuncture is feasible and safe for the treatment of #IBS-D,” Ling-Yu Qi, MM, and colleagues wrote in @JAMANetworkOpen #diarrhea #GITwitter #MedTwitter https://t.co/XerRKVkdFE

  • Mashup Score: 0

    Specific and nonspecific acupoint acupuncture improved symptoms of diarrhea among a small subset of patients with irritable bowel syndrome, according to results from a pilot study reported in JAMA Network Open. “Available treatments target IBS symptoms rather than underlying pathophysiological mechanisms, and additional improvements in the testing methods are still necessary. All these

    Tweet Tweets with this article
    • Specific and nonspecific #acupoint #acupuncture improved symptoms of #diarrhea among a small subset of patients with #irritablebowelsyndrome, according to results from a pilot study reported in @JAMANetworkOpen #IBS #GITwitter #Medtwitter https://t.co/XerRKVkdFE

  • Mashup Score: 0

    CHARLOTTE, N.C. — Daily treatment with Xifaxan over 2 weeks improved stool consistency and fecal urgency in adults with irritable bowel syndrome-diarrhea, according to a poster at the ACG Annual Scientific Meeting. “This research was conducted to evaluate rifaximin treatment for simultaneously improving IBS-D symptoms of fecal urgency and loose or watery stool consistency as a unique

    Tweet Tweets with this article
    • #ICYMI: Daily #Xifaxan (#rifaximin, @SalixPharma) improves fecal urgency, stool consistency in adults with #IBSD #ACG2022 #GITwitter #MedTwitter #diarrhea https://t.co/URQmJI5wgD